Peptide Therapy for Midlife Women: What the Science Actually Says

The word "peptides" is showing up everywhere in women's health conversations right now: in menopause forums, in wellness newsletters, in direct-to-consumer ads, and increasingly, in clinical offices. If you are a woman navigating perimenopause or menopause, the chances are good that you have either been asked about peptides, seen them promoted on social media, or started wondering whether they belong in your own health picture.

The interest is not unfounded. But the marketing has outpaced the evidence in important ways, and many women are making decisions without a clear understanding of what these compounds are, how they are regulated, and what questions to ask before moving forward.

As a licensed pharmacist and integrative wellness practitioner working with midlife women, I want to give you an honest orientation to this space: where the science is solid, where it is still developing, and what it means to use these therapies responsibly.

What Is a Peptide, and How Does It Work?

A peptide is a chain of amino acids, specifically a chain of between two and roughly 50 amino acids bonded together. Longer chains become proteins. Shorter ones, at two amino acids or more, are peptides.

That structural definition matters because it shapes how peptides behave in the body. Peptides function primarily as signaling molecules. They carry messages between cells, influencing downstream processes in ways that are both targeted and far-reaching. A peptide is not a single switch that turns one thing on or off. It is more like a communication sent into a network, capable of affecting multiple pathways simultaneously.

Peptides are distinct from hormones, though the two categories overlap. Hormones tend to have more complex chemical structures, including ring-based and steroid configurations. Peptides are specifically those amino acid chains. Some peptides are hormones, and some hormones are peptides, which is part of what makes the category feel confusing from the outside. The important thing to understand is that peptides are cellular messengers, and that they operate at the mitochondrial level in ways that make them pharmacologically meaningful.

Peptides Are Not New

This is perhaps the most important contextual point to establish: peptide therapy is not a recent invention. Insulin is a peptide, and it has been in clinical use for over a hundred years. GLP-1 receptor agonists, the compounds behind semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), received their first FDA approval in 2005. There is more than two decades of clinical data on GLP-1s specifically, even though their cultural moment only arrived recently.

What has changed is not the existence of these compounds. What has changed is access, the reach of direct-to-consumer wellness marketing, and a rapidly growing body of preclinical and early-stage clinical research on a broader range of peptides. The science is moving quickly. So is the marketing. And the two are not always in sync.

GLP-1s: What Midlife Women Need to Know

GLP-1 receptor agonists are the most well-researched peptides in current clinical use for weight management, and they are also the category most aggressively marketed to midlife women. The research supports their effectiveness. A 2025 analysis found that perimenopausal women in their 40s and early 50s lost similar amounts of weight on these medications as women in other reproductive stages, confirming that hormonal changes do not prevent them from working. A 2024 study published in Menopause found that postmenopausal women on both semaglutide and hormone therapy lost significantly more weight than those on semaglutide alone.

GLP-1s work primarily by reducing appetite and food noise, the persistent preoccupation with food that some people experience as an almost constant cognitive load. For the right candidate, these medications can make sustainable lifestyle change significantly more accessible. They are not, however, a substitute for that lifestyle change.

The muscle loss conversation that is not happening loudly enough

For midlife women, the most clinically important thing to understand about GLP-1s is this: weight loss on these medications is not automatically fat loss. Muscle tissue decreases alongside fat, and for women in perimenopause and menopause, that distinction carries real consequences.

A 2025 RAND Corporation analysis flagged this as one of the most critical and understudied risks of GLP-1 use in perimenopausal women specifically. We already contend with declining estrogen and its effects on muscle and bone. Muscle mass and bone density accelerate their decline after menopause, with some research showing muscle loss of one to two percent per year in postmenopausal women. Adding significant lean mass loss on top of that baseline creates downstream risk for reduced bone density, impaired metabolic function, and increased fracture risk. These are not theoretical concerns. They are clinically documented.

A well-managed GLP-1 protocol monitors lean body mass, not only the number on a scale. It includes guidance on protein intake and resistance training as non-negotiable components. Research consistently supports targeting protein at the upper end of clinical recommendations and incorporating at least two to three resistance training sessions per week for women using these medications in midlife.

Women who discontinue GLP-1s without building sustainable habits typically regain the weight. The outcome is often worse than where they started: because muscle was lost during treatment but not rebuilt when weight returned, body fat percentage ends up higher than at baseline. This is why both the evidence and thoughtful clinical practice frame GLP-1s as a tool within a broader plan, not a solution that stands alone.

On compounded GLP-1s: what the regulatory landscape currently looks like

The compounded semaglutide and tirzepatide market grew rapidly when name-brand manufacturers could not keep up with demand. The FDA had placed both medications on its shortage list in 2022, permitting compounding pharmacies to produce them at a fraction of the commercial cost. As of early 2025, the FDA resolved both shortages and began enforcing wind-down deadlines for compounders.

The regulatory picture remains active. Compounding pharmacies have continued to produce modified formulations by adding ingredients such as glycine or vitamin B12, which technically moves the product outside the "essential copy" category that triggers prohibition. These products are not the same compound as the brand-name medications, and they are not FDA-approved. That does not make them inherently unsafe, but it does mean the patient is accepting a different level of regulatory scrutiny than they would with a commercially manufactured medication. Anyone considering a compounded GLP-1 should understand that distinction and should be working with a prescriber who is tracking their response and monitoring their body composition.

Beyond GLP-1s: A Brief Overview of Other Peptides of Interest

A growing number of women are asking about peptides beyond GLP-1s, particularly those being discussed in functional medicine and longevity communities. The evidence base for most of these is substantially thinner than for GLP-1s. Human trials exist, but they are generally small and in many cases preliminary. What follows is an honest orientation to the compounds most frequently discussed, along with the regulatory context that is easy to miss when scrolling through a wellness feed.

BPC-157 and TB-500

BPC-157 (Body Protection Compound-157) is derived from a protein found in human gastric juice. Preclinical research has examined it for tissue repair, gut mucosal healing, joint recovery, and inflammation. TB-500 (Thymosin Beta-4) is similarly studied for tissue regeneration and injury recovery. These two are frequently discussed together and are sometimes marketed as a combination protocol for active recovery.

The regulatory situation for both has been in flux. Both were previously placed in FDA Category 2, indicating safety concerns, but in April 2026 the FDA removed them from that category following withdrawal of their nominations. They have not been moved to the approved compounding list. Neither is FDA-approved or has a recognized USP monograph. A 2024 systematic review in the American Journal of Sports Medicine found that clinical data on BPC-157 were limited and that in-human safety remains incompletely established. WADA has banned both compounds under its unapproved substances category.

This is a space worth watching as the evidence and regulation continue to evolve. It is not a space to navigate without qualified clinical oversight.

GHK-Cu (Copper Peptide)

GHK-Cu is a naturally occurring copper-binding tripeptide with preclinical research interest in collagen and elastin synthesis, skin remodeling, antioxidant activity, and potentially joint and hair health. It is already present in many topical skincare products; injectable formulations work systemically. Clinical evidence in humans is limited, and long-term safety data for injectable forms are lacking. For women over 40 with interest in connective tissue support and skin integrity, this compound generates legitimate scientific interest, but the evidence base does not yet support confident clinical recommendations beyond topical use.

Growth Hormone Secretagogues (sermorelin, tesamorelin, ipamorelin)

This class of compounds does not introduce synthetic growth hormone directly into the body. Instead, they signal the pituitary gland to increase its own growth hormone production, which naturally declines with age. Sermorelin is FDA-approved for use in growth hormone deficiency in children and has a USP monograph, which makes it one of the more clearly permissible peptides for compounding under current 503A regulations. Tesamorelin holds FDA approval for a specific indication in HIV-associated lipodystrophy. Ipamorelin is under ongoing review.

The potential clinical rationale in midlife women involves addressing what is sometimes called "somatopause," the age-related decline in growth hormone that can contribute to body composition changes, reduced recovery, and sleep disruption. Research on these compounds suggests potential benefits for sleep quality, lean muscle preservation, and exercise recovery, though the clinical cost-benefit remains under evaluation and use requires individualized assessment. These compounds are typically dosed in the evening before sleep, timed to align with the body's largest natural growth hormone pulse during early sleep.

The Provider Question

The peptide space currently has no standardized certification requirement for prescribers. A licensed physician or nurse practitioner can begin offering peptides with zero additional training. That is the regulatory reality, and it is worth taking seriously when you are making decisions about your own care.

A few principles that can help you evaluate any provider offering peptide therapy:

Source matters. Prescription peptides from licensed 503A compounding pharmacies are the appropriate standard. You should never be mixing your own peptides at home. If a provider hands you a kit to reconstitute with bacteriostatic water yourself, that is not a prescription product. A properly prepared compound arrives ready to use.

Ask about training directly. Ask how many patients the provider has worked with using these compounds, what outcomes they have observed, and what adverse effects they have encountered. A provider practicing responsibly will not be unsettled by these questions.

Look for individualized protocols. Your health history, your goals, and your current physiology should drive the decisions. A provider who offers the same protocol to everyone, or who is simply escalating doses on a preset schedule without monitoring your response, is not approaching this carefully.

For GLP-1s specifically: a provider focused on the lowest effective dose, lean mass monitoring, and nutritional support is taking a more thoughtful approach than one who defaults to standard escalation regardless of individual response.

What This Means for You

Peptides are cellular messengers that operate at a level of biological complexity that genuinely warrants respect. GLP-1s have a well-established evidence base and represent a clinically meaningful option for women with appropriate indications, particularly when used within a protocol that includes protein, resistance training, and regular monitoring. The broader category of research-stage peptides offers interesting possibilities that are not yet matched by the evidence needed for confident clinical recommendations.

The women I work with are intelligent, motivated, and often doing a great deal of their own research. My goal in this article is to help that research land on solid ground: grounded in the actual science, realistic about what is known and unknown, and oriented toward the kind of clinical decision-making that protects your long-term health.

If you are considering peptide therapy of any kind, work with a provider who is tracking your response, who is honest about the limits of current evidence, and who is treating your whole health picture rather than a single outcome measure. The questions you are asking are the right ones. Keep asking them.

This article was informed in part by a conversation with Dr. Jill White, PharmD, a pharmacist specializing in peptide therapy. You can learn more about her GLP-1 mentorship program at jillwhitecoaching.com and her peptide protocol membership at peptidemembership.com. Women Mastering Midlife listeners can use code VICTORIA25 for 25% off the membership fee.

This content is for educational purposes only and does not constitute medical advice. Consult with a qualified healthcare provider before beginning any new treatment.

References

1. RAND Corporation. GLP-1 Agonists in Perimenopause: Unique Risks and Potential Opportunities. August 2025.

2. Hurtado MD, Tama E, et al. Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause. 2024;31(4):266-274.

3. Mikdachi H, Dunsmoor-Su R. GLP-1 receptor agonists for weight loss for perimenopausal and postmenopausal women: current evidence. Current Opinion in Obstetrics and Gynecology. 2025.

4. Frontiers in Aging. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. March 2026.

5. MDPI International Journal of Molecular Sciences. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions. April 2026.

6. FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. Updated 2025.

7. Pharmacy Times. FDA Moves to Permanently Close the Door on Compounded GLP-1s. May 2026.

8. New Drug Loft / VLS Pharmacy. Recent Regulatory Updates on Compounded Peptide Injections. May 2026.

9. Frier Levitt. Regulatory Status of Peptide Compounding in 2025. January 2026.